A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer
about
Growth factor and signaling pathways and their relevance to prostate cancer therapeuticsAndrogen receptor activation in castration-recurrent prostate cancer: the role of Src-family and Ack1 tyrosine kinasesSRC: marker or actor in prostate cancer aggressivenessEMT, CTCs and CSCs in tumor relapse and drug-resistanceRecent advances in bone-targeted therapies of metastatic prostate cancerTranscription Factor STAT3 as a Novel Molecular Target for Cancer Prevention.Identification of DW532 as a novel anti-tumor agent targeting both kinases and tubulin.Current treatments and novel therapeutic targets for castration resistant prostate cancer with bone metastasisPathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments.Targeting synthetic lethality between the SRC kinase and the EPHB6 receptor may benefit cancer treatment.Non-Genomic Actions of the Androgen Receptor in Prostate CancerSrc promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures.Assessment of anticancer-treatment outcome in patients with metastatic castration-resistant prostate cancer-going beyond PSA and imaging, a systematic literature review.Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ERα-negative Breast Cancers to Tamoxifen through ERα Reexpression.A 4-Phenoxyphenol Derivative Exerts Inhibitory Effects on Human Hepatocellular Carcinoma Cells through Regulating Autophagy and Apoptosis Accompanied by Downregulating α-Tubulin Expression.Early investigational tubulin inhibitors as novel cancer therapeutics.Drug discovery in advanced prostate cancer: translating biology into therapy.Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trialBone-Targeted Therapies in Cancer-Induced Bone Disease.Antitumor Effect of KX-01 through Inhibiting Src Family Kinases and Mitosis.Impact of Phosphoproteomics in the Era of Precision Medicine for Prostate Cancer.
P2860
Q26827975-6AD6B0B9-494D-43D7-BB75-2D333A2352F1Q26866135-84EBDDA0-55EC-449C-91EC-80C31AE63333Q27012541-16D1EF9B-1E32-45F8-9988-698DE189CA6BQ28082935-E0577D73-01B0-415C-88A0-7E3384CC31F9Q33703763-00243B8E-6B37-4587-8419-26EC0483E200Q33820278-0D31C96F-17E3-4DC7-B882-667727541EFAQ33869726-28CA5898-0BF2-481C-B08A-92EA92F5AE87Q34448130-04C57B40-A92E-4EEF-9EE3-12F1A92E2FE2Q37187646-CFE0FA40-0432-4D1E-9C89-78ED70F93E6EQ37580359-EADB8CFB-6096-45D6-B4A3-52A853EEB2EAQ37588620-62CCAF5E-B560-41AB-B988-6BD268BD7D70Q37705831-D0161B47-94B9-486A-A213-AFA59791F7BBQ38555581-B1D9CE1A-03E4-4529-B919-6DFF8B31A2BDQ38656581-55E92DC7-35BC-4A14-A112-DD7063264894Q38680790-C83C0471-B79A-42DB-B9B6-C268D271C428Q38836161-D549AFA3-B9C1-4AFC-9A00-B07013BC6967Q38839110-2BE0F6EC-7976-4431-9232-384AEF628B8EQ41082307-1BA0B812-330B-4DF7-B4C9-C342B01ACB8BQ48110513-8EEDE7F7-BF6D-4BDC-9254-A3F2464F7332Q49800452-238852B7-78B9-4456-BD9A-33D982333F03Q50420907-D46EBFD0-5010-4B46-834E-9AFCF0D81293
P2860
A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
A phase 2 study of KX2-391, an ...... tion-resistant prostate cancer
@ast
A phase 2 study of KX2-391, an ...... tion-resistant prostate cancer
@en
A phase 2 study of KX2-391, an ...... tion-resistant prostate cancer
@nl
type
label
A phase 2 study of KX2-391, an ...... tion-resistant prostate cancer
@ast
A phase 2 study of KX2-391, an ...... tion-resistant prostate cancer
@en
A phase 2 study of KX2-391, an ...... tion-resistant prostate cancer
@nl
prefLabel
A phase 2 study of KX2-391, an ...... tion-resistant prostate cancer
@ast
A phase 2 study of KX2-391, an ...... tion-resistant prostate cancer
@en
A phase 2 study of KX2-391, an ...... tion-resistant prostate cancer
@nl
P2093
P2860
P1476
A phase 2 study of KX2-391, an ...... tion-resistant prostate cancer
@en
P2093
David G Hangauer
Edwin M Posadas
Elisabeth I Heath
Emmanuel S Antonarakis
Gerald J Fetterly
Gregory E Wilding
Justine Y Bruce
Lyn M Dyster
Michael A Carducci
P2860
P2888
P304
P356
10.1007/S00280-013-2079-Z
P577
2013-01-13T00:00:00Z
P6179
1021996107